The strong response to a specialized RFP like this one is a testament to the dedication and focus that many in the cancer research community are now placing on rare diseases like WM, and to the generosity of donors who give to the IWMF to support such efforts.
When announcing the Amyloidosis RFP in December, IWMF President Carl Harrington said, “This RFP represents an extension of our search to improve the quality of life for WMers. While amyloid affects only a small percentage of WMers, we are able to fund this research due to the generous support of a single donor. We expect that WM researchers will aggressively compete again to secure funding from us.” Scientific reviews of Amyloidosis in WM applications will be completed in the spring in conjunction with the review of the applications from the IWMF-LLS Strategic Research Roadmap RFP. Announcement of the new project award will occur in June 2017. The funding for the project is anticipated to begin during the four-month period, July-October 2017.
To learn more about Amyloidosis in WM, see these past articles from the IWMF Torch:
SERUM FREE LIGHT CHAIN TESTING AND WALDENSTRÖM MACROGLOBULINEMIA
AMYLOIDOSIS ASSOCIATED WITH WALDENSTRÖM DISEASE OR IgM-MGUS